GB835638A - Insulin crystal suspensions having a protracted effect - Google Patents

Insulin crystal suspensions having a protracted effect

Info

Publication number
GB835638A
GB835638A GB35737/57A GB3573757A GB835638A GB 835638 A GB835638 A GB 835638A GB 35737/57 A GB35737/57 A GB 35737/57A GB 3573757 A GB3573757 A GB 3573757A GB 835638 A GB835638 A GB 835638A
Authority
GB
United Kingdom
Prior art keywords
crystallization
crystals
insulin
metals
insulin crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB35737/57A
Inventor
Ja Rgen Schlichtkrull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Terapeutisk Laboratorium AS
Original Assignee
Novo Terapeutisk Laboratorium AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Terapeutisk Laboratorium AS filed Critical Novo Terapeutisk Laboratorium AS
Publication of GB835638A publication Critical patent/GB835638A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An injectable insulin preparation with a protracted effect comprises a suspension of insulin crystals derived wholly or partly from bovine pancreas glands and having the form of sharpedged rhombohedrons limited by plane crystal faces, such that the suspended insulin crystals at pH 6.5-7.5 of the p suspension medium contain chemically bound within the crystal lattice less than 5 atoms per unit cell of crystallization-promoting metals. The insulin crystals may be produced by crystallization as described in Specification 733,740 in an aqueous medium containing from 0.2-4.0 mols. per litre of halogen, such as the chlorides, bromides or iodides of alkali metals, alkaline earth metals and ammonia, or by crystallization in presence of trithanolamine hydrochloride, urea or formamide. The crystals are preferably produced with the employment of zinc as crystallization-promoting metal. Other specified crystallization-promoting metals are nickel, cadmium, cobalt, copper. The suspension medium may be made isotonic with sodium chloride and include a preserving agent, such as methyl-p-hydroxybenzoate, and may be buffered with an acetate, citrate or phosphate buffer. Insulin crystals in the form of stars, deformed rhombohydrons, rhombohedral twins or lemons may be also suspended in the aqueous medium, as may insulin crystals from swine pancreas. Crystals having a predetermined size distribution may be employed. Specification 709,927 also is referred to.
GB35737/57A 1956-12-01 1957-11-15 Insulin crystal suspensions having a protracted effect Expired GB835638A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK835638X 1956-12-01

Publications (1)

Publication Number Publication Date
GB835638A true GB835638A (en) 1960-05-25

Family

ID=8153173

Family Applications (1)

Application Number Title Priority Date Filing Date
GB35737/57A Expired GB835638A (en) 1956-12-01 1957-11-15 Insulin crystal suspensions having a protracted effect

Country Status (2)

Country Link
CY (1) CY215A (en)
GB (1) GB835638A (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118355A1 (en) 2013-02-04 2014-08-07 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10470459B2 (en) 2014-05-28 2019-11-12 Ipabc Ltd Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US10028910B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9839675B2 (en) 2013-02-04 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2014118355A1 (en) 2013-02-04 2014-08-07 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP3747426A1 (en) 2013-02-04 2020-12-09 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US10610595B2 (en) 2014-01-09 2020-04-07 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US10470459B2 (en) 2014-05-28 2019-11-12 Ipabc Ltd Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients

Also Published As

Publication number Publication date
CY215A (en) 1961-03-02

Similar Documents

Publication Publication Date Title
GB835638A (en) Insulin crystal suspensions having a protracted effect
GB1134615A (en) Gold electroplating bath
GB1214245A (en) Explosive compositions
GB1126734A (en) Articles of furniture upholstery supports and a method of mounting said supports
ES459003A1 (en) Method for seeding super-saturated sugar solution to effect crystallization
GB1387175A (en) Salts of iodomethanesulphonic acid
GB709927A (en) Improved process for producing insulin preparations with protracted effect
GB889769A (en) Slowly acting insulin preparation in crystalline form
GB766995A (en) Improvements in or relating to the production of insulin crystals
GB929220A (en) Gold plating
GB1206901A (en) A flux for zincking, tinning and leading
GB901675A (en) Process for improving the storage qualities of conserved whole-blood
GB1111563A (en) Methods for preparing n-benzyl-n',n"-dimethylguanidine
ES363778A1 (en) Magnesium slat of 5-methyl-3-(2,6-dichlorophenyl)-4-isoxazolyl-penicillin
GB1514996A (en) Fish-hooks assembly
SU527080A1 (en) Method of chemical nickel plating
Kitada et al. Geophysical constraints on the submarine volcanic activity around a hydrothermal area in the Mid-Okinawa Trough
USD164438S (en) Mayer girdle
GB838768A (en) Method of obtaining schoenite from kainite mineral
GB740131A (en) Process for coating graphite powder with a copper-lead alloy
GB169631A (en) Improvements relating to picker buffers of looms for weaving
GB834120A (en) Process for weaving non-elastic curtain tapes with hook tubes
USD175569S (en) Toy animal figure
GB845982A (en) Improvements relating to methods of melting and refining glass
GB874452A (en) Preservation of natural rubber latex